Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

@article{Bachelot2012RandomizedPI,
  title={Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.},
  author={Thomas Bachelot and C{\'e}line Bourgier and Claire Cropet and Isabelle Laure Ray-Coquard and Jes{\'u}s Mar{\'i}a Corona Ferrero and Gilles Freyer and Sophie Abadie-Lacourtoisie and J-C. Eymard and Marc Debled and Dominique Spa{\"e}th and Eric Legouffe and Djelila Allouache and Claude El Kouri and {\'E}ric Pujade-Lauraine},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 22},
  pages={
          2718-24
        }
}
PURPOSE Cross-talk between signal transduction pathways likely contributes to hormone resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian target of rapamycin, has restored sensitivity in endocrine-resistance models and shown anticancer activity in early-phase mBC clinical trials. This analysis evaluated efficacy and safety of everolimus in combination with tamoxifen in patients with mBC resistant to aromatase inhibitors (AIs). PATIENTS AND METHODS This… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 247 CITATIONS

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 25 Highly Influenced Citations

  • Averaged 31 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Similar Papers

Loading similar papers…